Table 2.
Details of ceftaroline fosamil treatment during index hospitalization
| Treatment variable | Patients (n = 185) |
|---|---|
| Ceftaroline fosamil line of therapy, n (%) | |
| 1 | 50 (27.0) |
| 2 | 49 (26.5) |
| 3 | 46 (24.9) |
| ≥4 | 40 (21.5) |
| Duration of treatment, days, median (range) | 7 (2–35) |
| Time from admission to first dose, days, median (range) | 1.9 (0–36) |
| Time from symptom onset to first dose, days, median (range) | 6 (0–38) |
| Daily dose, mg, median (range) | 1200 (200–1800) |
| Treatment type, n (%)a | |
| Empirical | 138 (74.6) |
| Definitive/specific | 41 (22.0) |
| Monotherapy/combination therapy, n (%) | |
| Monotherapy | 56 (30.3) |
| Combination therapyb | 129 (69.7) |
| Aminoglycoside | 3 (2.3) |
| β-lactam | 8 (6.2) |
| Carbapenem | 7 (5.4) |
| Ceftriaxone | 5 (3.9) |
| Cephalosporin | 1 (0.8) |
| Glycopeptide | 5 (3.9) |
| Macrolide | 2 (1.6) |
| β-lactam/combination | 36 (27.9) |
| Sulphonamide | 57 (44.2) |
| Clindamycin | 5 (3.9) |
| Other | 5 (3.9) |
| Administration location, n (%) | |
| ICU | 66 (35.7) |
| General ward | 115 (62.2) |
| At home | 1 (0.5) |
| Medical clinic | 30 (16.2) |
a n = 179 (data not available for six patients).
b n = 99 (data not available for 30 patients).